Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

An FDA committee’s September 2024 vote to limit the use of Merck’s Keytruda and BMS’ Opdivo in stomach and esophageal cancers ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

In this short teaser, BioSpace's Head of Insights Lori Ellis talks to CBER Director Peter Marks and Tom Whitehead, Co-Founder ...

Staff cuts could leave IGM Biosciences with fewer than 55 employees. The company is also halting development of two ...

Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...

After the successful development of mavacamten and the sale of MyoKardia to BMS in 2020, former executives of the biotech are ...

The Biotech Ecosystem Venture Fund will combine the sourcing capabilities of venture capital firm Andreessen Horowitz (a16z) ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Concurrently, a preprint from the industry-backed Vital Transformation found a 50% drop in company investments into ...

Eli Lilly’s idiopathic pulmonary fibrosis deal with Mediar is centered around MTX-463, an anti-WISP1 antibody that early ...